{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=gadoteridol", "query": { "intervention": "gadoteridol" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 17, "total_pages": 2, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=gadoteridol&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-08T20:50:38.969Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04879628", "title": "Proof-of-concept Study for SAR441344 (Frexalimab) in Relapsing Multiple Sclerosis", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Sclerosis" ], "interventions": [ { "name": "SAR441344 IV", "type": "DRUG" }, { "name": "placebo IV", "type": "DRUG" }, { "name": "SAR441344 SC", "type": "DRUG" }, { "name": "placebo SC", "type": "DRUG" }, { "name": "MRI contrast-enhancing preparations", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 129, "start_date": "2021-06-07", "completion_date": "2027-08-23", "has_results": true, "last_update_posted_date": "2025-09-30", "last_synced_at": "2026-09-08T20:50:38.969Z", "location_count": 4, "location_summary": "Phoenix, Arizona • Tampa, Florida • Charlotte, North Carolina + 1 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tampa", "state": "Florida" }, { "city": "Charlotte", "state": "North Carolina" }, { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT04879628" }, { "nct_id": "NCT05357833", "title": "Novel Imaging Markers in SPMS", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Secondary Progressive Multiple Sclerosis", "Multiple Sclerosis, Secondary Progressive", "Multiple Sclerosis" ], "interventions": [ { "name": "Ferumoxytol infusion", "type": "DRUG" }, { "name": "Gadoteridol", "type": "DRUG" }, { "name": "MRI Brain and Cervical Spine", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "DRUG", "DIAGNOSTIC_TEST" ], "sponsor": "University of Utah", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "35 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "35 Years to 65 Years" }, "enrollment_count": 11, "start_date": "2022-06-01", "completion_date": "2023-09-01", "has_results": false, "last_update_posted_date": "2026-08-13", "last_synced_at": "2026-09-08T20:50:38.969Z", "location_count": 1, "location_summary": "Salt Lake City, Utah", "locations": [ { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT05357833" }, { "nct_id": "NCT03396822", "title": "Meningeal Inflammation on 7T MRI as a Tool for Measuring and Predicting Ocrelizumab Response in Multiple Sclerosis", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Multiple Sclerosis" ], "interventions": [ { "name": "Gadoteridol", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Maryland, Baltimore", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 24, "start_date": "2018-09-24", "completion_date": "2023-05-25", "has_results": true, "last_update_posted_date": "2024-02-28", "last_synced_at": "2026-09-08T20:50:38.969Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT03396822" }, { "nct_id": "NCT05915728", "title": "A Study to Compare How Well Gadoquatrane Works and Its Safety With an Already Available Contrast Agent for MRI in People With Any Known or Suspected Problems of the Body (Except Brain or Spinal Cord-related Problems)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Contrast Enhancement in Magnetic Resonance Imaging", "Non-central Nervous System Pathology" ], "interventions": [ { "name": "Gadoquatrane (BAY1747846)", "type": "DRUG" }, { "name": "Gadobutrol", "type": "DRUG" }, { "name": "Gadoterate meglumine", "type": "DRUG" }, { "name": "Gadoteridol", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 410, "start_date": "2023-07-24", "completion_date": "2024-06-01", "has_results": true, "last_update_posted_date": "2026-08-20", "last_synced_at": "2026-09-08T20:50:38.969Z", "location_count": 9, "location_summary": "Birmingham, Alabama • Indian Wells, California • Orange, California + 6 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Indian Wells", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Farmington", "state": "Connecticut" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT05915728" }, { "nct_id": "NCT04608812", "title": "Convection-enhanced Delivery of OS2966 for Patients With High-grade Glioma Undergoing a Surgical Resection", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Glioma, Malignant", "High Grade Glioma", "Glioblastoma", "Glioblastoma Multiforme", "Anaplastic Astrocytoma" ], "interventions": [ { "name": "OS2966", "type": "DRUG" }, { "name": "Gadoteridol", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "OncoSynergy, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 7, "start_date": "2021-03-02", "completion_date": "2023-02-27", "has_results": false, "last_update_posted_date": "2023-08-18", "last_synced_at": "2026-09-08T20:50:38.969Z", "location_count": 1, "location_summary": "Tampa, Florida", "locations": [ { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04608812" }, { "nct_id": "NCT04373564", "title": "Effect on Body Movement and Mental Skills in Patients Who Received Gadolinium-based Contrast Media for Magnetic Resonance Examination Multiple Times Within 5 Years", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Motor Function", "Cognitive Function", "Contrast Media" ], "interventions": [ { "name": "Motor Tests", "type": "PROCEDURE" }, { "name": "Cognitive Tests", "type": "PROCEDURE" }, { "name": "Unenhanced-MRI of the brain", "type": "PROCEDURE" }, { "name": "Gadolinium Measurements", "type": "PROCEDURE" }, { "name": "Gadoxetate disodium", "type": "DRUG" }, { "name": "Gadobenate dimeglumine", "type": "DRUG" }, { "name": "Gadodiamide", "type": "DRUG" }, { "name": "Gadoterate meglumine", "type": "DRUG" }, { "name": "Gadobutrol", "type": "DRUG" }, { "name": "Gadoteridol", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "Guerbet", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "64 Years", "sex": "ALL", "summary": "18 Years to 64 Years" }, "enrollment_count": 2076, "start_date": "2021-03-24", "completion_date": "2028-12-31", "has_results": false, "last_update_posted_date": "2026-01-22", "last_synced_at": "2026-09-08T20:50:38.969Z", "location_count": 16, "location_summary": "Scottsdale, Arizona • New Haven, Connecticut • Chicago, Illinois + 11 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Peoria", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04373564" }, { "nct_id": "NCT00709852", "title": "Safety and Efficacy of Gadobutrol 1.0 Molar (Gadavist) in Patients for Central Nervous System (CNS) Imaging", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diagnostic Imaging", "Central Nervous System Diseases" ], "interventions": [ { "name": "Gadobutrol (Gadavist, Gadovist, BAY86-4875)", "type": "DRUG" }, { "name": "Gadoteridol (ProHance)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 402, "start_date": "2008-06", "completion_date": "2009-04", "has_results": true, "last_update_posted_date": "2014-12-30", "last_synced_at": "2026-09-08T20:50:38.969Z", "location_count": 24, "location_summary": "Birmingham, Alabama • Tuscaloosa, Alabama • Los Gatos, California + 20 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tuscaloosa", "state": "Alabama" }, { "city": "Los Gatos", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "Santa Rosa", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00709852" }, { "nct_id": "NCT02359097", "title": "Steady State Blood Volume Maps Using Ferumoxytol Non-stoichiometric Magnetite MRI in Imaging Patients With Glioblastoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Glioblastoma" ], "interventions": [ { "name": "Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Ferumoxytol", "type": "DRUG" }, { "name": "Gadoteridol", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "OHSU Knight Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 29, "start_date": "2015-01-06", "completion_date": "2021-03-12", "has_results": false, "last_update_posted_date": "2022-03-17", "last_synced_at": "2026-09-08T20:50:38.969Z", "location_count": 2, "location_summary": "Columbus, Ohio • Portland, Oregon", "locations": [ { "city": "Columbus", "state": "Ohio" }, { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT02359097" }, { "nct_id": "NCT01613417", "title": "Comparison of Prohance® With Gadovist®/Gadavist™ in Magnetic Resonance Imaging (MRI) of the Brain", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Brain Disease" ], "interventions": [ { "name": "gadoteridol", "type": "DRUG" }, { "name": "gadobutrol", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bracco Diagnostics, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 229, "start_date": "2012-08", "completion_date": "2014-04", "has_results": true, "last_update_posted_date": "2015-07-01", "last_synced_at": "2026-09-08T20:50:38.969Z", "location_count": 1, "location_summary": "Teaneck, New Jersey", "locations": [ { "city": "Teaneck", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT01613417" }, { "nct_id": "NCT03750188", "title": "Evaluation of Safety and Efficacy of ProHance in Pediatric Patients <2yrs", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Central Nervous System Diseases", "Central Nervous System Neoplasms" ], "interventions": [ { "name": "ProHance", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bracco Diagnostics, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Day", "maximum_age": "2 Years", "sex": "ALL", "summary": "1 Day to 2 Years" }, "enrollment_count": 125, "start_date": "2018-11-01", "completion_date": "2019-10-16", "has_results": false, "last_update_posted_date": "2020-01-23", "last_synced_at": "2026-09-08T20:50:38.969Z", "location_count": 1, "location_summary": "Charleston, South Carolina", "locations": [ { "city": "Charleston", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT03750188" } ] }